The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
Ability to comprehend and willingness to sign a written ICF for the study.
Aged 18 to 65 years, inclusive, at the time of signing the ICF.
Body mass index between 18.0 and 30.5 kg/m2, inclusive.
No clinically significant findings on screening evaluations (clinical, laboratory, and ECG).
History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
Participants with any history of an autoimmune disease diagnosis.
History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
History or presence of an abnormal ECG.